Gilbert & Cook Inc. trimmed its holdings in Baxter International Inc (NYSE:BAX) by 4.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,810 shares of the medical instruments supplier’s stock after selling 146 shares during the quarter. Gilbert & Cook Inc.’s holdings in Baxter International were worth $246,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Stonebridge Capital Advisors LLC boosted its stake in shares of Baxter International by 4.3% during the 2nd quarter. Stonebridge Capital Advisors LLC now owns 2,886 shares of the medical instruments supplier’s stock worth $236,000 after acquiring an additional 120 shares in the last quarter. SeaCrest Wealth Management LLC boosted its stake in shares of Baxter International by 2.0% during the 2nd quarter. SeaCrest Wealth Management LLC now owns 6,117 shares of the medical instruments supplier’s stock worth $501,000 after acquiring an additional 122 shares in the last quarter. Baker Ellis Asset Management LLC boosted its stake in shares of Baxter International by 8.3% during the 2nd quarter. Baker Ellis Asset Management LLC now owns 1,625 shares of the medical instruments supplier’s stock worth $133,000 after acquiring an additional 125 shares in the last quarter. Schmidt P J Investment Management Inc. boosted its stake in shares of Baxter International by 4.2% during the 3rd quarter. Schmidt P J Investment Management Inc. now owns 3,095 shares of the medical instruments supplier’s stock worth $271,000 after acquiring an additional 125 shares in the last quarter. Finally, Boston Private Wealth LLC boosted its stake in shares of Baxter International by 1.8% during the 2nd quarter. Boston Private Wealth LLC now owns 7,346 shares of the medical instruments supplier’s stock worth $602,000 after acquiring an additional 129 shares in the last quarter. 83.45% of the stock is currently owned by institutional investors.

Several equities research analysts have recently issued reports on BAX shares. Deutsche Bank started coverage on shares of Baxter International in a research note on Monday, October 21st. They set a “buy” rating and a $109.00 target price on the stock. Wells Fargo & Co set a $95.00 price target on shares of Baxter International and gave the company a “buy” rating in a research note on Friday, July 26th. UBS Group decreased their price target on shares of Baxter International from $98.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, October 28th. Raymond James raised their price target on shares of Baxter International from $84.00 to $95.00 and gave the company an “outperform” rating in a research note on Friday, July 26th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating on shares of Baxter International in a research note on Tuesday, September 10th. Five investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $90.14.

Baxter International stock traded up $0.51 during midday trading on Friday, reaching $78.51. The company had a trading volume of 3,017,392 shares, compared to its average volume of 2,768,937. The company has a market capitalization of $39.56 billion, a P/E ratio of 25.74, a P/E/G ratio of 2.00 and a beta of 0.97. Baxter International Inc has a 12-month low of $61.40 and a 12-month high of $89.93. The firm’s fifty day simple moving average is $84.08 and its 200-day simple moving average is $82.11. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.78 and a quick ratio of 2.10.

In other Baxter International news, Director James R. Gavin III sold 7,950 shares of the stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $87.63, for a total value of $696,658.50. Following the completion of the sale, the director now owns 40,932 shares in the company, valued at approximately $3,586,871.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Andrew Frye sold 3,332 shares of the stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $88.00, for a total transaction of $293,216.00. Following the completion of the sale, the senior vice president now owns 16,391 shares of the company’s stock, valued at approximately $1,442,408. The disclosure for this sale can be found here. Insiders sold a total of 17,396 shares of company stock worth $1,528,575 over the last ninety days. 0.70% of the stock is currently owned by corporate insiders.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

See Also: What is intrinsic value?

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.